RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer

RAS mutant (MT) metastatic colorectal cancer (mCRC) is resistant to MEK1/2 inhibition and remains a difficult-to-treat group. Therefore, there is an unmet need for novel treatment options for RASMT mCRC. RALA and RALB GTPases function downstream of RAS and have been found to be key regulators of sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Khawaja, Hajrah, Campbell, Andrew, Roberts, Jamie Z., Javadi, Arman, O’Reilly, Paul, McArt, Darragh, Allen, Wendy L., Majkut, Joanna, Rehm, Markus, Bardelli, Alberto, Di Nicolantonio, Federica, Scott, Christopher J., Kennedy, Richard, Vitale, Nicolas, Harrison, Timothy, Sansom, Owen J., Longley, Daniel B., Evergren, Emma, Van Schaeybroeck, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596570/
https://www.ncbi.nlm.nih.gov/pubmed/33122623
http://dx.doi.org/10.1038/s41419-020-03131-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596570/
https://www.ncbi.nlm.nih.gov/pubmed/33122623
http://dx.doi.org/10.1038/s41419-020-03131-3

Ejemplares similares